- 8 minutes ago
Houston Oncology Summit: Talking KRAS & pan-RAS inhibition with MD Anderson’s Ferdinandos Skoulidis
Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and the theoretical potential for pan-RAS inhibitors.
- 1 hour ago
Houston Oncology Summit: MD Anderson’s VP of industry relations talks about partnering
Ferran Prat describes what advantages MD Anderson offers to drug developers running trials, what makes a good partner, and areas of science
- 2 hours ago
Houston Oncology Summit: How the Cancer Focus Fund can help small biotechs get into phase 1 studies
Ross Barrett describes how the Cancer Focus Fund provides financing, advice, and help with getting into the clinic at MD Anderson.
- 4 hours ago
Houston Oncology Summit: Talking lung cancer advances with John Heymach
Dr. Heymach discusses KRAS, refined TKI matching, antibody-drug conjugates, cell therapies, and cancer vaccines.
- 3 days ago
Discussing the science of using transfer RNA for protein editing with hC Bioscience’s CEO
Leslie Williams explains how harnessing tRNA might be used for nonsense mutation diseases and for marking unwanted proteins for destruction.
- 3 days ago
Trekk Venture Partners' Brian Gallagher gives an update on the venture market
Brian Gallagher describes what it is like raising venture funds in biotech today and also offers areas of science that he is focused on.
- Sep 14
Baird’s Brian Skorney joins BiotechTV in New York for Analyst Thursdays
Brian Skorney discusses this week’s data from Neurocrine Biosciences and Crinetics, and comments on Amgen, Regeneron, and Arbutus.
